androstane-3,17-diol has been researched along with finasteride in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (6.67) | 18.7374 |
| 1990's | 7 (46.67) | 18.2507 |
| 2000's | 4 (26.67) | 29.6817 |
| 2010's | 3 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barbolt, TA; Dube, JY; Egy, MA; Frenette, G; Juniewicz, PE; Tremblay, RR | 1 |
| Buntinx, A; De Schepper, P; Giagulli, VA; Stoner, E; Vermeulen, A | 1 |
| Coakes, KE; Norman, RW; Rittmaster, RS; Wright, AS | 1 |
| de Lorenzo, D; Fruzzetti, F; Parrini, D; Ricci, C | 1 |
| Castello, R; Moghetti, P; Muggeo, M; Negri, C; Perrone, F; Tosi, F | 1 |
| Dallob, A; Ebel, DL; Geissler, LA; Gertz, BJ; Hafkin, B; Schwartz, JI; Tanaka, WK; Wang, DZ | 1 |
| Falsetti, L; Gambera, A | 1 |
| Carrington, P; Cole, GW; Cotterill, PC; Dallob, A; Drake, L; Epstein, ES; Fiedler, V; Geissler, L; Gencheff, C; Griffin, EI; Hordinsky, M; Jacobson, C; Kraus, SJ; Lowe, N; Pariser, DM; Stieglitz, S; Swinehart, J; Tanaka, W; Thiboutot, DM; Unger, WP; Vandormael, K; Waldstreicher, J; Weiss, D; Whiting, D | 1 |
| Castello, R; Dorizzi, R; Fortunato, A; Moghetti, P; Muggeo, M; Negri, C; Spiazzi, GG; Tosi, F | 1 |
| Reddy, DS | 1 |
| Gustafsson, JA; Imamov, O; Lopatkin, NA | 1 |
| Chien, B; Ramu, K; Reddy, DS; Venkatarangan, L | 1 |
| Chu, LW; Figg, WD; Goodman, PJ; Hoque, A; Hsing, AW; Kristal, AR; Lippman, SM; Neuhouser, ML; Patel, SK; Platz, EA; Reichardt, JK; Stanczyk, FZ; Tangen, CM; Thompson, IM; Till, C; Van Bokhoven, A | 1 |
| Soory, M; Suchak, A | 1 |
| Azen, CG; Pike, MC; Stanczyk, FZ | 1 |
8 trial(s) available for androstane-3,17-diol and finasteride
| Article | Year |
|---|---|
Androgen metabolism in men receiving finasteride before prostatectomy.
Topics: Androstane-3,17-diol; Combined Modality Therapy; Dihydrotestosterone; Double-Blind Method; Finasteride; Humans; Male; Preoperative Care; Prostate; Prostatectomy; Prostatic Hyperplasia; Testosterone | 1993 |
Outcome of long-term treatment with the 5 alpha-reductase inhibitor finasteride in idiopathic hirsutism: clinical and hormonal effects during a 1-year course of therapy and 1-year follow-up.
Topics: 5-alpha Reductase Inhibitors; Adult; Androstane-3,17-diol; Dihydrotestosterone; Enzyme Inhibitors; Female; Finasteride; Hirsutism; Humans; Luteinizing Hormone; Testosterone; Treatment Outcome | 1996 |
MK-386, an inhibitor of 5alpha-reductase type 1, reduces dihydrotestosterone concentrations in serum and sebum without affecting dihydrotestosterone concentrations in semen.
Topics: 5-alpha Reductase Inhibitors; Adolescent; Adult; Androstane-3,17-diol; Azasteroids; Dihydrotestosterone; Enzyme Inhibitors; Finasteride; Humans; Luteinizing Hormone; Male; Middle Aged; Sebum; Semen; Testosterone | 1997 |
Comparison of finasteride and flutamide in the treatment of idiopathic hirsutism.
Topics: Adolescent; Adult; Androgen Antagonists; Androstane-3,17-diol; Body Mass Index; Enzyme Inhibitors; Female; Finasteride; Flutamide; Hair; Hirsutism; Humans; Testosterone; Treatment Outcome | 1999 |
The effects of finasteride on scalp skin and serum androgen levels in men with androgenetic alopecia.
Topics: 5-alpha Reductase Inhibitors; Adolescent; Adult; Alopecia; Androgens; Androstane-3,17-diol; Dihydrotestosterone; Double-Blind Method; Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Scalp; Testosterone | 1999 |
Antiandrogen drugs lower serum prostate-specific antigen (PSA) levels in hirsute subjects: evidence that serum PSA is a marker of androgen action in women.
Topics: Adult; Androgen Antagonists; Androgens; Androstane-3,17-diol; Biomarkers; Double-Blind Method; Enzyme Inhibitors; Female; Finasteride; Flutamide; Hirsutism; Humans; Prostate-Specific Antigen; Spironolactone; Testosterone | 2000 |
Associations of serum sex steroid hormone and 5α-androstane-3α,17β-diol glucuronide concentrations with prostate cancer risk among men treated with finasteride.
Topics: 5-alpha Reductase Inhibitors; Aged; Androstane-3,17-diol; Case-Control Studies; Finasteride; Glucuronides; Gonadal Steroid Hormones; Humans; Male; Middle Aged; Prostatic Neoplasms; Risk; Sex Hormone-Binding Globulin | 2012 |
Effect of finasteride on serum levels of androstenedione, testosterone and their 5α-reduced metabolites in men at risk for prostate cancer.
Topics: 5-alpha Reductase Inhibitors; Aged; Androstane-3,17-diol; Androstenedione; Dihydrotestosterone; Finasteride; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Testosterone | 2013 |
7 other study(ies) available for androstane-3,17-diol and finasteride
| Article | Year |
|---|---|
Effects of androgen and antiandrogen treatment on canine prostatic arginine esterase.
Topics: 5-alpha Reductase Inhibitors; Androgen Antagonists; Androgens; Androstane-3,17-diol; Androstenes; Anilides; Animals; Azasteroids; Capsules; Carboxylic Ester Hydrolases; Dogs; Dose-Response Relationship, Drug; Estradiol; Finasteride; Flutamide; Hyperplasia; Injections, Intramuscular; Male; Nitriles; Pregnanes; Prostate; Prostatectomy; Pyrazoles; Tosyl Compounds | 1990 |
Hormonal effects of an orally active 4-azasteroid inhibitor of 5 alpha-reductase in humans.
Topics: 5-alpha Reductase Inhibitors; Administration, Oral; Adolescent; Adult; Androgens; Androstane-3,17-diol; Androstenes; Androsterone; Azasteroids; Capsules; Dihydrotestosterone; Drug Evaluation; Finasteride; Humans; Isomerism; Liver; Male; Steroids, Heterocyclic; Testosterone; Tetrahydrocortisol | 1989 |
Effects of finasteride, a 5 alpha-reductase inhibitor, on circulating androgens and gonadotropin secretion in hirsute women.
Topics: 5-alpha Reductase Inhibitors; Adolescent; Adult; Androgens; Androstane-3,17-diol; Cosyntropin; Dihydrotestosterone; Female; Finasteride; Follicle Stimulating Hormone; Hair; Hirsutism; Humans; Hydrocortisone; Luteinizing Hormone; Periodicity; Testosterone | 1994 |
Testosterone modulation of seizure susceptibility is mediated by neurosteroids 3alpha-androstanediol and 17beta-estradiol.
Topics: Androstane-3,17-diol; Animals; Aromatase Inhibitors; Chromatography; Convulsants; Dose-Response Relationship, Drug; Enzyme Inhibitors; Estradiol; Finasteride; Hippocampus; Letrozole; Male; Mass Spectrometry; Mice; Nitriles; Organ Culture Techniques; Patch-Clamp Techniques; Pentylenetetrazole; Rats; Receptors, GABA-A; Seizures; Testosterone; Triazoles | 2004 |
Estrogen receptor beta in prostate cancer.
Topics: 5-alpha Reductase Inhibitors; Androstane-3,17-diol; Animals; Antineoplastic Agents, Hormonal; Estrogen Receptor beta; Finasteride; Humans; Ligands; Male; Mice; Prostatic Neoplasms | 2004 |
A high-performance liquid chromatography-tandem mass spectrometry assay of the androgenic neurosteroid 3alpha-androstanediol (5alpha-androstane-3alpha,17beta-diol) in plasma.
Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; 5-alpha Reductase Inhibitors; Androstane-3,17-diol; Animals; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Finasteride; Mass Spectrometry; Rats; Reproducibility of Results; Testosterone | 2005 |
Anabolic potential of bone mineral in human periosteal fibroblasts using steroid markers of healing.
Topics: Adult; Androstane-3,17-diol; Animals; Biomarkers; Bone and Bones; Cattle; Dihydrotestosterone; Drug Interactions; Female; Fibroblasts; Finasteride; Humans; Male; Mice; Middle Aged; Minerals; Minocycline; Periosteum; Steroids; Testosterone; Wound Healing | 2013 |